Legal & General Group Plc Purchases Shares of 32,924 Enliven Therapeutics, Inc. $ELVN

Legal & General Group Plc acquired a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 2nd quarter, Holdings Channel reports. The fund acquired 32,924 shares of the company’s stock, valued at approximately $1,671,000.

Several other institutional investors also recently modified their holdings of ELVN. KBC Group NV bought a new position in shares of Enliven Therapeutics in the first quarter worth approximately $38,000. State of Wyoming bought a new stake in Enliven Therapeutics during the second quarter valued at approximately $96,000. FNY Investment Advisers LLC purchased a new position in Enliven Therapeutics in the 2nd quarter worth approximately $126,000. BNP Paribas Financial Markets increased its holdings in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares during the last quarter. Finally, Quantbot Technologies LP increased its holdings in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ELVN. Guggenheim dropped their price objective on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Barclays assumed coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They set an “overweight” rating and a $78.00 price target for the company. Stifel Nicolaus upped their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, William Blair started coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $75.00.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $59.32 on Monday. The stock has a market cap of $4.35 billion, a PE ratio of -35.52 and a beta of 0.30. The company’s fifty day moving average is $55.66 and its 200 day moving average is $44.31. Enliven Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.69 EPS for the current year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, Director Lori Kunkel sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the sale, the director owned 41,884 shares in the company, valued at approximately $2,114,723.16. The trade was a 19.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $58.58, for a total transaction of $352,534.44. Following the completion of the transaction, the chief financial officer owned 40,036 shares in the company, valued at $2,345,308.88. This represents a 13.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 186,849 shares of company stock worth $10,998,857 in the last ninety days. 3.00% of the stock is owned by company insiders.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.